Study of Trametinib in Advanced Cancer Patients With Hepatic Dysfunction

Titre officiel

A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction

Sommaire:

Cette étude est une étude de phase 1 (la première phase d'essai d'un médicament pour déterminer son degré d'innocuité) dont le but est de trouver la bonne dose de trametinib, médicament expérimental, pour les patients atteints de cancers solides et souffrant de divers niveaux de dysfonctionnement hépatique (du foie).

Description de l'essai

Primary Outcome:

  • Best dose (in mg) of trametinib for patients with varying degree of hepatic dysfunction receiving trametinib (mild, moderate and severe)
  • Maximum tolerated dose (MTD) (in mg) of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction
  • Dose-limiting toxicity (DLT) (in mg) of trametinib in advanced cancer patients with varying degrees of hepatic dysfunction
  • Levels of trametinib in the blood of all participants over 24-hours
Secondary Outcome:
  • Number of participants that respond to treatment
  • Types of molecular aberrations per patient
  • Number side effects in patients with normal liver function
  • Number side effects in patients with mild liver dysfunction
  • Number side effects in patients with moderate liver dysfunction
  • Number side effects in patients with severe liver dysfunction
Patients will be separated into the following groups: Group A: Normal hepatic function, Group B: Mild hepatic dysfunction, Group C: Moderate hepatic dysfunction, Group D: Severe hepatic dysfunction Groups of 3-6 patients to take part in each group will receive increasing doses of the study drug to until the best dose of study drug for each hepatic function group is found. Trametinib is an oral drug that works by blocking mitogen-activated extracellular signal regulated kinase (MEK) 1 and MEK 2. MEK1 and MEK2 are important proteins that are needed for the growth of cells. When these proteins are blocked, it is believed that the growth of cancer cells will stop and the cancer cells will then die.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer